share_log

Additional Considerations Required While Assessing APT Medical's (SHSE:688617) Strong Earnings

Additional Considerations Required While Assessing APT Medical's (SHSE:688617) Strong Earnings

在評估APT Medical(SHSE: 688617)的強勁收益時需要考慮其他因素
Simply Wall St ·  03/31 20:30

APT Medical Inc. (SHSE:688617) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders have noticed something concerning in the numbers.

APT Medical Inc.(上海證券交易所股票代碼:688617)宣佈了豐厚的利潤,但該股停滯不前。我們的分析表明,股東們注意到了一些令人擔憂的數字。

earnings-and-revenue-history
SHSE:688617 Earnings and Revenue History April 1st 2024
SHSE: 688617 2024 年 4 月 1 日的收益和收入歷史記錄

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

To properly understand APT Medical's profit results, we need to consider the CN¥45m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

爲了正確理解APT Medical的利潤業績,我們需要考慮不尋常項目帶來的4500萬元人民幣的收益。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們計算數千家上市公司的數字時,我們發現,特定年份中不尋常的項目所帶來的提振通常不會在第二年重演。考慮到這個名字,這並不奇怪。假設這些不尋常的項目在本年度不會再次出現,因此我們預計明年的利潤將疲軟(也就是說,在業務沒有增長的情況下)。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On APT Medical's Profit Performance

我們對APT Medical盈利表現的看法

We'd posit that APT Medical's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that APT Medical's statutory profits are better than its underlying earnings power. But the good news is that its EPS growth over the last three years has been very impressive. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Ultimately, this article has formed an opinion based on historical data. However, it can also be great to think about what analysts are forecasting for the future. At Simply Wall St, we have analyst estimates which you can view by clicking here.

我們認爲,APT Medical的法定收入並不能完全反映持續的生產力,這是因爲這個很大的不尋常項目。因此,我們認爲APT Medical的法定利潤可能好於其基礎盈利能力。但好消息是,其在過去三年中的每股收益增長非常令人印象深刻。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。最終,本文根據歷史數據形成了觀點。但是,考慮分析師對未來的預測也可能很好。在Simply Wall St,我們有分析師的估計,您可以點擊此處查看。

Today we've zoomed in on a single data point to better understand the nature of APT Medical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單個數據點,以更好地了解APT Medical利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論